Top 10 Pharmaceuticals markets in CanadaThe fastest-growing and largest of the 20 sized Pharmaceuticals markets in Canada, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $3 Bn | $27.3 Bn | 24.9% | – |
| 2 | Cell Based Immunotherapy | $1.3 Bn | $10.5 Bn | 23% | – |
| 3 | Cannabidiol (CBD) | $1.8 Bn | $8.3 Bn | 16.8% | – |
| 4 | Cannabis | $2.7 Bn | $9.6 Bn | 13.5% | – |
| 5 | Atopic Dermatitis Drugs | $898 Mn | $2.8 Bn | 12.2% | – |
| 6 | Oncology/Cancer Drugs | $14.2 Bn | $31.7 Bn | 8.4% | – |
| 7 | Anti-Aging | $7.1 Bn | $15.4 Bn | 8.1% | – |
| 8 | Diabetes Management | $6.2 Bn | $12.4 Bn | 7.1% | – |
| 9 | Alzheimer Drugs | $401 Mn | $774 Mn | 6.8% | – |
| 10 | Contraceptives Drugs | $2 Bn | $3.9 Bn | 6.8% | – |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $14.2 Bn | $31.7 Bn | 8.4% | – |
| 2 | Anti-Aging | $7.1 Bn | $15.4 Bn | 8.1% | – |
| 3 | Diabetes Management | $6.2 Bn | $12.4 Bn | 7.1% | – |
| 4 | Gastrointestinal Drugs | $4.3 Bn | $6.8 Bn | 4.6% | – |
| 5 | Asthma & COPD Drugs | $4 Bn | $5.9 Bn | 4% | – |
| 6 | Biosimilars | $3 Bn | $27.3 Bn | 24.9% | – |
| 7 | Cannabis | $2.7 Bn | $9.6 Bn | 13.5% | – |
| 8 | HIV Drugs | $2.4 Bn | $4.2 Bn | 5.8% | – |
| 9 | Contraceptives Drugs | $2 Bn | $3.9 Bn | 6.8% | – |
| 10 | Cancer Supportive Care Drugs | $2 Bn | $3.1 Bn | 4.7% | – |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 24.9% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (23%).
Oncology/Cancer Drugs is the largest, worth about $14.2 Bn in 2023 and $31.7 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.
US